Is Sol-Gel Technologies Ltd. (SLGL) Halal?

NASDAQ Healthcare Israel $223M
✗ NOT HALAL
Confidence: 90/100
Sol-Gel Technologies Ltd. (SLGL) is Not Halal under AAOIFI Standard 21. The company's impermissible income ratio of 12.43% exceeds the 5% threshold allowed under AAOIFI. Sol-Gel Technologies Ltd. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 0.6%
/ 30%
10.5%
/ 30%
1.6%
/ 30%
12.43%
/ 5%
✗ NOT HALAL
DJIM 0.6%
/ 33%
10.5%
/ 33%
1.6%
/ 33%
12.43%
/ 5%
✗ NOT HALAL
MSCI 3.6%
/ 33%
66.7%
/ 33%
10.0%
/ 33%
12.43%
/ 5%
✗ NOT HALAL
S&P 0.6%
/ 33%
10.5%
/ 33%
1.6%
/ 33%
12.43%
/ 5%
✗ NOT HALAL
FTSE 3.6%
/ 33%
66.7%
/ 33%
10.0%
/ 50%
12.43%
/ 5%
✗ NOT HALAL

Financial Highlights

EPS
$-2.19
P/B Ratio
9.7
EV/EBITDA
-26.7
EV: $200M
Revenue
$12M
Growth: 150.4%
Beta
1.2
High volatility
Current Ratio
4.4

Profitability

Gross Margin -17.6%
Operating Margin -497.8%
Net Margin -31.6%
Return on Equity (ROE) -23.7%
Return on Assets (ROA) -14.4%

Cash Flow & Balance Sheet

Operating Cash Flow-$14M
Free Cash Flow-$14M
Total Debt$1M
Debt-to-Equity4.3
Current Ratio4.4
Total Assets$36M

Price & Trading

Last Close$77.91
50-Day MA$75.27
200-Day MA$39.77
Avg Volume27K
Beta1.2
52-Week Range
$4.02
$97.97

About Sol-Gel Technologies Ltd. (SLGL)

CEO
Mr. Moshe Arkin
Employees
28
Sector
Healthcare
Industry
Biotechnology
Country
Israel
Exchange
NASDAQ
Market Cap
$223M
Currency
USD

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Sol-Gel Technologies Ltd. (SLGL) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Sol-Gel Technologies Ltd. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Sol-Gel Technologies Ltd.'s debt ratio?

Sol-Gel Technologies Ltd.'s debt ratio is 0.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.6%.

What are Sol-Gel Technologies Ltd.'s key financial metrics?

Sol-Gel Technologies Ltd. has a market capitalization of $223M, and revenue of $12M. The company maintains a gross margin of -17.6% and a net margin of -31.6%. Return on equity stands at -23.7%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.